Author Of 2 Presentations
LB1166 - Risk and outcomes of COVID-19 in patients with multiple sclerosis in Madrid Spain (ID 1480)
- V. Meca-Lallana
- L. Costa-Frossard
- C. Oreja-Guevara
- C. Aguirre
- E. Alba Suárez
- M. Gómez Moreno
- L. Borrega Canelo
- J. Sabín-Muñoz
- Y. Aladro
- A. Cárcamo Fonfría
- E. Rodríguez García
- J. Cuello
- E. Monreal
- S. Sainz de la Maza
- F. Perez Parra
- F. Valenzuela
- C. Lopez De Silanes
- L. Casanova Peño
- M. Martínez-Ginés
- M. Blasco Quílez
- A. Orviz García
- L. Villar
- C. Santiuste
- M. Espiño
- G. Fernandez-Dono
- V. Elvira
- I. Moreno-Torres
Abstract
Background
Infections are an important cause of hospitalization in patients with MS. Data on outcomes of COVID-19 in patients with MS are limited
Objectives
To quantify the risks of infection, hospitalization, admission to intensive care and death due to SARS-CoV-2 infection among patients with MS relative to the general population, and to identify factors associated with risk of hospitalization
Methods
A regional registry was created to collect data on incidence, hospitalization rates, intensive care unit (ICU) admission and death in patients with MS and COVID-19. National government outcomes and seroprevalence data were used for comparison.
Results
Two-hundred nineteen patients with MS were included in the registry, 51 of whom were hospitalized. The infection incidence rate (IR) was lower in patients with MS than the general population (adjusted IR ratio 0.78; 95% confidence interval: 0.70–0.80), but hospitalization rates were higher (adjusted relative risk 6.52 [6.13–7.04]). Disease severity was generally low, with only one ICU admission and five deaths. Males with MS had higher incidence rates and risk of hospitalization than females. No association was found between the use of any disease-modifying therapy (DMT) and hospitalization risk.
Conclusions
Patients with MS do not appear to have greater risks of SARS-CoV-2 infection or severe COVID-19 outcomes compared with the general population. The decision to start or continue DMT should be based on a careful risk-benefit assessment.
P0109 - microRNA expression and its association with disability and brain atrophy (ID 1255)
Abstract
Background
MicroRNAs (miRNAs) are endogenous, non coding, small RNAs with post-transcriptional regulating functions. They participate in several cellular processes, including inflammation, neurodegeneration and remyelination
Objectives
To correlate serum miRNAs profile expression with disability, cognitive functioning and brain volume in patients with remitting-relapsing multiple sclerosis (RRMS)
Methods
Cross-sectional study in RRMS patients on stable treatment with glatiramer acetate (GA) during at least 6 months.
We selected the 20 best miRNAs candidates for RRMS and cognitive dysfunction through simple topological analysis (Anaxomics ®). MiRNAs profile was determined with LNA-based PCR (Exiqon). Clinical variables were Expanded Disability Status Scale (EDSS), Symbol Digit Modalities Test (SDMT) and brain volume (whole brain volume, grey matter volume, white matter volume, cerebellum volume, basal ganglia volume and T1 lesion load volume) (automatic software NeuroQuant ®). Correlation was analyzed with Spearman correlation coefficient (r) (p<0,05; software: SPSS)
Results
We included 20 patients (13 women), age 38,2 (29,4, 47,8) years, duration of disease: 5,1 (1,5, 8,5) years, and time on GA 2,1 (0,8, 6) years. We found a pathogenic association between miR.146a.5p and has.mir.9.5p with EDSS (r:0,434, p=0,03; r:0,516, p=0,028); miR.146a.5p with SDMT (r:-0,476, p=0,016); has.mir.9.5p with thalamus (r:-0,545, p=0,036), and miR.200c.3p with pallidum and cerebellum (r:-0,675, p=0,002; r:-0,472, p=0,048).
Conclusions
MiRNAs could be useful biomarkers in multiple sclerosis. We would like to highlight the association of proinflammatory has.mir.9.5p with EDSS and thalamus volume. They are needed more studies to confirm this findings.